Gustavo Fonseca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gustavo Fonseca has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Warner
Florida Cancer Specialists & Research Institute
1 shared publication Amy Ming
Florida Cancer Specialists & Research Institute
1 shared publicationAshley Swanson
Bristol Myers Squibb
1 shared publicationAya Alajrash
Florida Cancer Specialists & Research Institute
1 shared publicationBradley J. Monk
Florida Cancer Specialists & Research Institute West Palm Beach Florida USA
1 shared publication- Chandni Patel
Florida Cancer Specialists & Research Institute Fort Myers Florida USA
1 shared publication
Latest Publications
- Open Access
- 9 August 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (8) , e70572
Understanding Cancer Clinical Trial Participation in Rural Communities: A Qualitative Focus Group Study
Background: Participation in cancer clinical trials is essential for advancing oncologic care, yet enrollment among rural populations remains disproportionately low. These communities face many hurdles including geographical distance from medical centers, healthcare workforce shortages, and deep‐seated medical mistrust that may contribute to survival inequities. Aims: To address these gaps, a Research Navigator program was launched through the Florida Cancer Specialists & Research Institute to engage rural Florida residents in focus group sessions to identify barriers to trial participation. Methods: Utilizing the Integrated Behavioral and Socioecological Framework (IBSF), the study conducted five semi‐structured focus groups with 30 participants recruited from rural Florida counties. Participants included cancer survivors, advocates, caregivers, and those currently in treatment. Discussions centered on knowledge, experiences, perceived barriers, and willingness to participate in cancer clinical trials. Results: Although most participants expressed awareness of cancer clinical trials, focus group discussions revealed misconceptions regarding trial purpose, process, and accessibility. Across groups, commonly reported barriers to participation included limited access to reliable transportation, financial concerns, and mistrust of medical professionals and healthcare systems. Thematic analysis of focus group transcripts yielded four themes: (A) perception and lived experience, (B) trial information dissemination, (C) enrollment impediments, and (D) intervention strategies and implementation. Conclusion: In rural settings, decisions regarding cancer clinical trial participation are shaped by a complex interplay of trust, logistics, and information access. This study emphasizes the importance of viewing trials as routine care and suggests that navigator‐led outreach and patient‐centric technology are essential for creating equitable access.
- 9 August 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (8) , e70572
Open AccessUnderstanding Cancer Clinical Trial Participation in Rural Communities: A Qualitative Focus Group Study
Background: Participation in cancer clinical trials is essential for advancing oncologic care, yet enrollment among rural populations remains disproportionately low. These communities face many hurdles including geographical distance from medical centers, healthcare workforce shortages, and deep‐seated medical mistrust that may contribute to survival inequities. Aims: To address these gaps, a Research Navigator program was launched through the Florida Cancer Specialists & Research Institute to engage rural Florida residents in focus group sessions to identify barriers to trial participation. Methods: Utilizing the Integrated Behavioral and Socioecological Framework (IBSF), the study conducted five semi‐structured focus groups with 30 participants recruited from rural Florida counties. Participants included cancer survivors, advocates, caregivers, and those currently in treatment. Discussions centered on knowledge, experiences, perceived barriers, and willingness to participate in cancer clinical trials. Results: Although most participants expressed awareness of cancer clinical trials, focus group discussions revealed misconceptions regarding trial purpose, process, and accessibility. Across groups, commonly reported barriers to participation included limited access to reliable transportation, financial concerns, and mistrust of medical professionals and healthcare systems. Thematic analysis of focus group transcripts yielded four themes: (A) perception and lived experience, (B) trial information dissemination, (C) enrollment impediments, and (D) intervention strategies and implementation. Conclusion: In rural settings, decisions regarding cancer clinical trial participation are shaped by a complex interplay of trust, logistics, and information access. This study emphasizes the importance of viewing trials as routine care and suggests that navigator‐led outreach and patient‐centric technology are essential for creating equitable access.
- Open Access
- 2 September 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 1357-1369
Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review
Erythropoiesis-stimulating agents (ESAs) are an established treatment for lower-risk myelodysplastic syndromes (LR-MDS). However, real-world data on the outcomes of patients with LR-MDS treated with ESAs are limited. This study describes treatment patterns and clinical outcomes in this population. This is a retrospective review of electronic medical records compiled from Florida Cancer Specialists & Research Institute databases. Inclusion criteria were: LR-MDS diagnosis (between January 2018 through December 2022), initiation of ESA treatment, ≥18 years at diagnosis, availability of ≥6 months of data prior to diagnosis, and ≥1 year of follow-up data. Patients treated with luspatercept prior to ESAs or enrolled in clinical trials during the study period were excluded. Patients were followed for 1 year from the initial diagnosis until loss to follow-up/death. Outcomes included treatment patterns (occurrence of and time to ESA failure, and time on ESA treatment after failure), and clinical outcomes related to ESA failure (hematologic improvement and transfusion independence), with ESA failure defined as a < 1.5 g/dL rise in hemoglobin or no decrease in red blood cell transfusions by 6-8 weeks of treatment. At baseline, of 359 eligible patients with LR-MDS most were male (65.2%), White (88.0%), non-transfusion dependent (74.9%), and had hemoglobin levels of 8-10 g/dL (56.3%) and ring sideroblasts <5% (59.3%). Most patients (68.0%) experienced ESA failure, with a median of 56.0 days from ESA initiation to failure, and a median of 466.5 days receiving ESA treatment after failure. Hematologic improvement was observed in 33.7% of patients. In this real-world evaluation of ESA treatment in a population with LR-MDS, only one-third of patients experienced hematologic improvement and two-thirds of patients remained on ESA treatment for ≥1 year after failure. These results demonstrate high rates of ESA failure and indicate patients in community oncology settings in the US may be continuing with ESA treatment despite failure.
- 2 September 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 1357-1369
Open AccessTreatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review
Erythropoiesis-stimulating agents (ESAs) are an established treatment for lower-risk myelodysplastic syndromes (LR-MDS). However, real-world data on the outcomes of patients with LR-MDS treated with ESAs are limited. This study describes treatment patterns and clinical outcomes in this population. This is a retrospective review of electronic medical records compiled from Florida Cancer Specialists & Research Institute databases. Inclusion criteria were: LR-MDS diagnosis (between January 2018 through December 2022), initiation of ESA treatment, ≥18 years at diagnosis, availability of ≥6 months of data prior to diagnosis, and ≥1 year of follow-up data. Patients treated with luspatercept prior to ESAs or enrolled in clinical trials during the study period were excluded. Patients were followed for 1 year from the initial diagnosis until loss to follow-up/death. Outcomes included treatment patterns (occurrence of and time to ESA failure, and time on ESA treatment after failure), and clinical outcomes related to ESA failure (hematologic improvement and transfusion independence), with ESA failure defined as a < 1.5 g/dL rise in hemoglobin or no decrease in red blood cell transfusions by 6-8 weeks of treatment. At baseline, of 359 eligible patients with LR-MDS most were male (65.2%), White (88.0%), non-transfusion dependent (74.9%), and had hemoglobin levels of 8-10 g/dL (56.3%) and ring sideroblasts <5% (59.3%). Most patients (68.0%) experienced ESA failure, with a median of 56.0 days from ESA initiation to failure, and a median of 466.5 days receiving ESA treatment after failure. Hematologic improvement was observed in 33.7% of patients. In this real-world evaluation of ESA treatment in a population with LR-MDS, only one-third of patients experienced hematologic improvement and two-thirds of patients remained on ESA treatment for ≥1 year after failure. These results demonstrate high rates of ESA failure and indicate patients in community oncology settings in the US may be continuing with ESA treatment despite failure.
- Open Access
- 8 August 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (12) , 852-862
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014
- 8 August 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (12) , 852-862
Open AccessPomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014